Furthermore, considering that tumor-infiltrated T-cells of BsTE:OT-1 T-cells (Fig. 1E) or hBsTE:hPBMC (Fig. 6F, G) were enhanced because of αPD-L1 BsTE, the tumor-infiltrating hCD19 CAR-T cell analysis of the hCD19 MC38-bearing mice showed that αPD-L1 BsTE:CAR-T (CD45+CD8+Thy1.1+) cell treatment enhanced the accumulation of hCD19 CAR-T cells in the tumor tissue when compared with the control group and hCD19 CAR-T and αhCD19 BsTE:CAR-T cell treatment (Fig. 7D). This evidence concerns the gene CD8A and neoplasm.